DIETARY SUPPLEMENTS
Découvrez 08 - Slim
Your ally for a slimmer figure and healthy weight
Journal
For decades, Parkinson’s disease was framed as a disorder of movement — a condition defined by tremor, rigidity, and the progressive loss of motor control. That description is not wrong. It is simply incomplete.
What has emerged over the past fifteen years is a far more complex picture: Parkinson’s is not only a disease of dopamine deficiency, but a disorder of cellular homeostasis. It involves mitochondrial dysfunction, chronic low-grade inflammation, impaired protein clearance, immune dysregulation, and increasingly, the gut–brain axis. In that sense, it belongs to a broader category of age-related conditions where biological resilience progressively fails at multiple levels simultaneously.
This shift matters, because it fundamentally changes where we look — and where we intervene.
At its core, Parkinson’s still involves the degeneration of dopaminergic neurons in the substantia nigra. The resulting dopamine deficit explains the classic motor symptoms — slowness of movement, rigidity, resting tremor. But these symptoms only emerge once a significant proportion of neurons has already been lost. By the time diagnosis is made, neurodegeneration is well underway.
What precedes that stage is a cascade of cellular dysfunction.
One of the central mechanisms is the accumulation of misfolded alpha-synuclein, a protein that, under pathological conditions, aggregates into toxic structures known as Lewy bodies. These aggregates do not remain confined. They appear to propagate, influencing neighboring neurons and progressively spreading across neural networks. This dynamic helps explain why Parkinson’s evolves from a focal motor disorder into a multisystem condition affecting cognition, autonomic function, sleep, and mood.
Parallel to this, mitochondrial dysfunction plays a decisive role. Neurons — particularly dopaminergic neurons — are highly energy-dependent. When mitochondrial quality control fails, defective mitochondria accumulate, increasing oxidative stress and compromising cellular survival. Genetic forms of Parkinson’s, involving PINK1 or Parkin, have been instrumental in uncovering this vulnerability, but the same mechanisms are increasingly recognized in sporadic cases.
Overlaying these processes is chronic neuroinflammation. Once considered secondary, inflammation is now understood as an active driver of disease progression. Microglial activation, immune signaling, and systemic inflammatory inputs create a feedback loop that amplifies neuronal damage over time.
Taken together, these mechanisms define Parkinson’s not as a single-pathway disorder, but as a convergence of failures in energy production, protein handling, and immune regulation.
One of the most significant conceptual shifts in Parkinson’s research concerns its possible origin.
The traditional model assumes that pathology begins in the brain. Increasingly, data suggest that this may not always be the case.
Many patients report non-motor symptoms — particularly constipation — years, sometimes decades, before motor signs appear. This temporal gap has drawn attention to the gastrointestinal system, and more specifically, to the enteric nervous system and the gut microbiome.
The gut is not a passive organ. It hosts a dense neural network, communicates directly with the brain through the vagus nerve, and interacts continuously with the immune system. It is also home to the microbiome, a metabolically active ecosystem capable of influencing inflammation, barrier integrity, and neural signaling.
Within this context, the hypothesis that Parkinson’s may, in some cases, originate in the gut has gained traction.
Alpha-synuclein pathology has been observed in enteric neurons. Experimental models show that pathological forms of the protein can propagate along neural pathways. Epidemiological data suggest that disrupting vagal communication may alter disease risk. None of these elements alone is definitive. Together, they outline a coherent and biologically plausible framework.
The emerging view is not that Parkinson’s always starts in the gut, but that it may follow different trajectories — with a “gut-first” subtype in which peripheral mechanisms play an early role, and a “brain-first” subtype where central processes dominate from the outset.
The most robust human data come from studies comparing the gut microbiome of Parkinson’s patients to that of healthy controls.
The first major study, published in 2015, demonstrated clear compositional differences, including a reduction in Prevotella species and correlations between microbial profiles and disease severity. Since then, multiple cohorts across different populations have confirmed that Parkinson’s is associated with a distinct microbial signature.
However, the field has evolved beyond simple taxonomic descriptions.
What matters is not only which bacteria are present, but what they do.
Metagenomic analyses reveal consistent functional alterations: reduced capacity for fiber fermentation, changes in short-chain fatty acid production, altered bile acid metabolism, and shifts in pathways involved in inflammation and neurotransmitter precursors. This functional perspective helps reconcile apparent inconsistencies between studies, showing that different microbial compositions can lead to similar metabolic outcomes.
The turning point came with experimental work demonstrating that the microbiome can actively influence disease expression.
In a landmark study, mice genetically predisposed to Parkinson-like pathology developed significantly fewer motor symptoms when raised without microbiota. When these mice were colonized with gut bacteria — especially bacteria derived from Parkinson’s patients — their symptoms worsened, along with neuroinflammation and alpha-synuclein aggregation.
This was a critical shift.
The microbiome was no longer just associated with the disease. It became a potential modulator of its progression.
One of the key mechanisms linking the gut to the brain is intestinal barrier integrity.
In several studies, Parkinson’s patients show increased intestinal permeability. This allows microbial components, such as lipopolysaccharides, to enter circulation and trigger systemic immune responses. These signals can reach the brain, activate microglia, and contribute to a sustained inflammatory state.
This is where the different layers of the disease converge.
Gut dysfunction, immune activation, and neuronal vulnerability are not separate phenomena. They form a continuous axis.
Short-chain fatty acids — particularly butyrate — illustrate this connection well.
Produced by microbial fermentation of dietary fibers, these molecules regulate intestinal barrier function, immune balance, and, indirectly, brain function. In Parkinson’s, several studies report reduced abundance of SCFA-producing bacteria and altered metabolite profiles.
The implications are significant.
A shift in microbial metabolism can influence inflammation, energy regulation, and cellular resilience — precisely the processes that are impaired in Parkinson’s.
Another emerging dimension is the interaction between the microbiome and pharmacology.
Levodopa, the mainstay treatment for Parkinson’s, must reach the brain to be effective. Yet certain gut bacteria can metabolize levodopa before it is absorbed, reducing its availability. This introduces a new variable in treatment response — one that is not neurological, but microbial.
It suggests that part of the variability observed in patients may be explained not only by disease stage or genetics, but by the composition and activity of their microbiome.
This is where expectations must be carefully calibrated.
Diet, fiber intake, probiotics, and microbiome-directed interventions are all being explored. Fecal microbiota transplantation has entered early clinical trials. Some results are encouraging, but they remain preliminary.
At this stage, the microbiome is best understood as a modifiable interface, not a standalone therapeutic solution.
It offers a way to influence inflammation, metabolism, and possibly disease progression — but not yet a way to stop the disease.
What ultimately emerges from this body of work is a redefinition of Parkinson’s.
It is not simply a disorder of movement, nor even a purely neurological disease. It is a systemic condition rooted in the progressive failure of cellular systems that maintain stability over time.
Mitochondria lose efficiency. Protein quality control declines. Inflammation becomes chronic. The microbiome shifts. The immune system becomes dysregulated.
The brain reflects these changes — it does not exist outside of them.
The microbiome does not replace the classical understanding of Parkinson’s. It extends it.
It connects previously separate domains — neurology, immunology, metabolism, gastroenterology — into a unified framework. It introduces new mechanisms, new biomarkers, and potentially new therapeutic targets.
Most importantly, it shifts the perspective.
Parkinson’s is no longer a disease confined to the brain.
It is a disease of systems — and among those systems, the gut has become impossible to ignore.
[1] Inserm. Parkinson’s Disease (Overview)
https://www.inserm.fr/dossier/parkinson-maladie/
[2] The Lancet. Parkinson’s Disease Series (2024)
https://www.thelancet.com/series-do/parkinsons-disease
[3] Morris HR, et al. The pathogenesis of Parkinson’s disease. The Lancet, 2024
https://www.thelancet.com/journals/lancet/article/PIIS0140-6736(23)01478-2/abstract
[4] Narendra DP. PINK1–Parkin and mitochondrial quality control. Annual Review of Biochemistry, 2024
https://pubmed.ncbi.nlm.nih.gov/39358449/
[5] Tansey MG, Romero-Ramos M. Inflammation and immune dysfunction in Parkinson disease. Nature Reviews Immunology, 2022
https://www.nature.com/articles/s41577-022-00684-6
[6] Tan AH, et al. The microbiome–gut–brain axis in Parkinson disease. Nature Reviews Gastroenterology & Hepatology, 2022
https://pubmed.ncbi.nlm.nih.gov/35750883/
[7] Scheperjans F, et al. Gut microbiota are related to Parkinson’s disease and clinical phenotype. Movement Disorders, 2015
https://pubmed.ncbi.nlm.nih.gov/25476529/
[8] Sampson TR, et al. Gut microbiota regulate motor deficits and neuroinflammation in a model of Parkinson’s disease. Cell, 2016
https://pubmed.ncbi.nlm.nih.gov/27912057/
[9] Wallen ZD, et al. Metagenomics of Parkinson’s disease implicates the gut microbiome in multiple disease mechanisms. Nature Communications, 2022
https://www.nature.com/articles/s41467-022-34667-x
[10] Maini Rekdal V, et al. Discovery and inhibition of an interspecies gut bacterial pathway for Levodopa metabolism. Science, 2019
https://pubmed.ncbi.nlm.nih.gov/31196984/
[11] Loh JS, et al. Microbiota–gut–brain axis and its therapeutic applications in neurodegenerative disease. Signal Transduction and Targeted Therapy, 2024
https://www.nature.com/articles/s41392-024-01743-1
[12] Svensson E, et al. Vagotomy and subsequent risk of Parkinson’s disease. Annals of Neurology, 2015
https://pubmed.ncbi.nlm.nih.gov/26031848/
[13] Meissner WG, et al. Trial of Lixisenatide in Early Parkinson’s Disease. New England Journal of Medicine, 2024
https://www.nejm.org/doi/full/10.1056/NEJMoa2312323
[14] Milekovic T, et al. A spinal cord neuroprosthesis for locomotor deficits due to Parkinson’s disease. Nature Medicine, 2023
https://pubmed.ncbi.nlm.nih.gov/37932548/
[15] Siderowf A, et al. α-synuclein seed amplification assay in Parkinson’s disease. The Lancet Neurology, 2023
https://pubmed.ncbi.nlm.nih.gov/37059509/